Amylyx Pharmaceuticals, Inc. (AMLX) Stock Analysis and Metrics

Amylyx Pharmaceuticals

NASDAQ: AMLX

$18.41 ▲ +0.82 (+4.66%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap2.01 Bn

P/E-10.07

Div. Yield0.00

Add ratio to table…

About

Amylyx Pharmaceuticals Inc is a clinical stage pharmaceutical company dedicated to developing novel therapies for communities with high unmet medical need. The company focuses on endocrine conditions and neurodegenerative diseases where existing treatments are insufficient. Its pipeline includes the glucagon like peptide 1 receptor antagonist avexitide which is being evaluated for post bariatric hypoglycemia and congenital hyperinsulinism. Avexitide has received Breakthrough Therapy Designation from the US Food and Drug Administration for both indications and also holds Orphan Drug Designation for hyperinsulinemic hypoglycemia. Another pipeline asset is the oral fixed dose combination AMX0035 comprising sodium phenylbutyrate and taurursodiol which is being studied in Wolfram syndrome. AMX0035 aims to mitigate endoplasmic reticulum stress and mitochondrial dysfunction. The antisense oligonucleotide AMX0114 targets calpain 2 and is being investigated in amyotrophic lateral sclerosis. A next generation glucagon like peptide 1 receptor antagonist AMX0318 is being developed for longer acting administration in post bariatric hypoglycemia and other rare diseases. Amylyx conducts pre clinical and clinical programs to assess safety efficacy and biological activity of these candidates.

Amylyx Pharmaceuticals Inc is currently a clinical stage company and has not yet commercialized any therapeutic product. As a result it has not generated revenue from product sales. The company finances its research and development through external support such as grants and collaborations. Breakthrough T1D has provided funding to academic partners for a trial of AMX0035 in type 1 diabetes and Amylyx supplies the investigational drug for that study. Additionally the company pursues other research alliances and seeks government or foundation grants to advance its pipeline.

Amylyx Pharmaceuticals Inc occupies a niche in the rare disease space focusing on endocrine and neurodegenerative disorders that currently have limited approved therapies. The company estimates that post bariatric hypoglycemia affects approximately 160 000 individuals in the United States while Wolfram syndrome affects about 3 000 people in the United States and amyotrophic lateral sclerosis affects as many as 30 000 adults in the United States. Its competitive advantages stem from novel mechanisms of action regulatory designations such as Breakthrough Therapy and Orphan Drug designations and a growing patent estate that includes hundreds of issued patents worldwide. Key competitors include larger biopharma firms pursuing similar indications as well as academic groups developing alternative therapies. The firm believes that success will depend on factors such as efficacy safety profile dosing cost promotional support and intellectual property protection.

Amylyx Pharmaceuticals Inc serves patients suffering from rare endocrine and neurodegenerative disorders including those with post bariatric hypoglycemia congenital hyperinsulinism Wolfram syndrome and amyotrophic lateral sclerosis. The company also works with health care providers clinical trial sites and research institutions that participate in its studies. Amylyx engages with patient advocacy groups such as the congenital hyperinsulinism community and collaborates with organizations like Breakthrough T1D for external research initiatives. Additionally the company has partnered with Gubra A S for the discovery and development of AMX0318. No specific customer names are disclosed in the filing.

Investment Thesis

▲ Bull case

Amylyx Pharmaceuticals is positioned to capture a significant unmet need in post-bariatric hypoglycemia (PBH) with avexitide, as evidenced by the company's deep engagement with the patient and provider community, which has revealed a profound burden of disease and a high intent to treat among endocrinologists should an approved therapy become available. The initiation of the U.S. Expanded Access Program (EAP) prior to Phase III top-line data, despite the typical industry pattern of waiting for positive results, underscores both the urgency felt by the PBH community and the company's confidence in avexitide's efficacy based on five prior positive trials. This proactive approach not only addresses immediate patient suffering but also builds critical real-world evidence and physician familiarity that could accelerate adoption upon potential approval. Furthermore, the ongoing NDA preparation work, driven by an experienced regulatory team with global approval backgrounds, is de-risking the path to submission and could compress the typical 6-9 month timeline between positive Phase III data and filing, potentially enabling an earlier commercial launch in 2027 than currently anticipated by the market.
The recent peer-reviewed publication of Week 24 and Week 48 results from the HELIOS trial for AMX0035 in Wolfram syndrome provides a valuable, underappreciated catalyst that extends beyond the primary focus on avexitide. The demonstration of continued improvements in pancreatic beta cell function, glycemic control, and stabilization of visual acuity over 48 weeks, coupled with favorable safety and meaningful patient-reported outcomes, reinforces AMX0035's potential to alter the disease trajectory in a population with no FDA-approved options. This progress supports the company's stated plan for a Phase 3 trial in Wolfram syndrome and highlights the breadth of Amylyx's pipeline beyond its lead asset. Importantly, the Orphan Drug Designations from both the FDA and European Commission for AMX0035 in Wolfram syndrome reduce competitive risk and could provide significant commercial incentives, including market exclusivity and tax credits, should the program advance successfully. The market may be underestimating the value of this pipeline diversification, which could mitigate reliance on a single product and provide multiple near-term inflection points.
Amylyx's commercial readiness efforts for avexitide, led by Chief Commercial Officer Dan Monahan with a proven track record in launching major endocrine and metabolic therapies (Rexulti, Cosentyx, Lantus, Actonel), are advancing in lockstep with clinical milestones and are grounded in rigorous market analysis. The company's independent claims analysis and field engagements have consistently supported the estimate of approximately 160,000 people living with PBH in the U.S. who have undergone sleeve gastrectomy or Roux-en-Y gastric bypass, a figure rooted in growing published literature and validated through direct engagement with treatment centers. The anticipated ICD-10 code for PBH, effective October 1, 2026, while not deemed essential for commercialization, will enhance patient tracking across electronic medical record systems and improve epidemiology tracking, thereby strengthening long-term market access and reimbursement discussions. Management's focus on disease state education launching this summer, targeting centers of excellence first before expanding to the broader endocrinology community, reflects a strategic, phased approach to market development that could optimize launch efficiency and uptake.

Amylyx Pharmaceuticals is positioned to capture a significant unmet need in post-bariatric hypoglycemia (PBH) with avexitide, as evidenced by the company's deep engagement with the patient and provider community, which has revealed a profound burden of disease and a high intent to treat among endocrinologists should an approved therapy become available. The initiation of the U.S. Expanded Access Program (EAP) prior to Phase III top-line data, despite the typical industry pattern of waiting for positive results, underscores both the urgency felt by the PBH community and the company's confidence in avexitide's efficacy based on five prior positive trials. This proactive approach not only addresses immediate patient suffering but also builds critical real-world evidence and physician familiarity that could accelerate adoption upon potential approval. Furthermore, the ongoing NDA preparation work, driven by an experienced regulatory team with global approval backgrounds, is de-risking the path to submission and could compress the typical 6-9 month timeline between positive Phase III data and filing, potentially enabling an earlier commercial launch in 2027 than currently anticipated by the market.
The recent peer-reviewed publication of Week 24 and Week 48 results from the HELIOS trial for AMX0035 in Wolfram syndrome provides a valuable, underappreciated catalyst that extends beyond the primary focus on avexitide. The demonstration of continued improvements in pancreatic beta cell function, glycemic control, and stabilization of visual acuity over 48 weeks, coupled with favorable safety and meaningful patient-reported outcomes, reinforces AMX0035's potential to alter the disease trajectory in a population with no FDA-approved options. This progress supports the company's stated plan for a Phase 3 trial in Wolfram syndrome and highlights the breadth of Amylyx's pipeline beyond its lead asset. Importantly, the Orphan Drug Designations from both the FDA and European Commission for AMX0035 in Wolfram syndrome reduce competitive risk and could provide significant commercial incentives, including market exclusivity and tax credits, should the program advance successfully. The market may be underestimating the value of this pipeline diversification, which could mitigate reliance on a single product and provide multiple near-term inflection points.
Amylyx's commercial readiness efforts for avexitide, led by Chief Commercial Officer Dan Monahan with a proven track record in launching major endocrine and metabolic therapies (Rexulti, Cosentyx, Lantus, Actonel), are advancing in lockstep with clinical milestones and are grounded in rigorous market analysis. The company's independent claims analysis and field engagements have consistently supported the estimate of approximately 160,000 people living with PBH in the U.S. who have undergone sleeve gastrectomy or Roux-en-Y gastric bypass, a figure rooted in growing published literature and validated through direct engagement with treatment centers. The anticipated ICD-10 code for PBH, effective October 1, 2026, while not deemed essential for commercialization, will enhance patient tracking across electronic medical record systems and improve epidemiology tracking, thereby strengthening long-term market access and reimbursement discussions. Management's focus on disease state education launching this summer, targeting centers of excellence first before expanding to the broader endocrinology community, reflects a strategic, phased approach to market development that could optimize launch efficiency and uptake.

▼ Bear case

Despite Amylyx's optimistic outlook, the company faces significant execution risk in the pivotal Phase III LUCIDITY trial for avexitide, as the trial's design relies heavily on historical data from five prior positive studies that may not be fully replicable in a larger, more diverse population. The management team acknowledged the conservative powering assumptions (35% effect size target despite prior 50-64% observed effects) and retained power for up to a 50% placebo effect, which they admitted they do not expect in PBH, suggesting awareness of potential variability in treatment response. Furthermore, the avoidance of commenting on baseline characteristics or placebo response during the Q&A, coupled with the reliance on blinded study data, raises questions about whether the enrolled population truly mirrors the prior successful trials, especially given the chronic and progressive nature of PBH where baseline hypoglycemia frequency and severity could significantly influence outcomes. Any failure to meet the primary endpoint or a result driven by high placebo response would severely undermine the investment thesis, particularly given the company's cash runway is explicitly tied to this milestone.
The commercial opportunity for avexitide in PBH, while touted as substantial at 160,000 patients in the U.S., remains highly uncertain and may be overestimated due to the nascent state of disease recognition and diagnostic practices. Management's claims analysis depends on identifying patients with bariatric surgery and documented nondiabetic hypoglycemia, then layering on symptoms like fatigue, dizziness, and seizures—criteria that may lack specificity and could inadvertently include patients with other causes of hypoglycemia or unrelated comorbidities. The dependence on centers of excellence for initial launch, with acknowledgment of only 50-60 patients per center, suggests a highly concentrated patient base that could limit early commercial scale and prolong the path to meaningful revenue. Moreover, the company's own admission that the ICD-10 code is not necessary for commercialization implies current diagnostic and coding practices are insufficient for reliable patient identification, posing a persistent barrier to market penetration that disease state education alone may not overcome quickly.
Amylyx's financial position, while currently supported by $279.8 million in cash and marketable securities as of Q1 2026, reflects a declining trend from $317 million at the end of the prior year, driven by increased operating expenses tied to the LUCIDITY trial and pre-launch activities. The $4 million milestone payment to Gubra for AMX0035 identification, coupled with rising R&D and SG&A expenditures, underscores the cash burn associated with advancing multiple pipeline programs concurrently. While management states this capital funds the runway into 2028, this projection is contingent on the successful and timely execution of the LUCIDITY trial, NDA submission, and potential approval—any delay in these milestones would rapidly erode the cash buffer. Additionally, the lack of discussion regarding potential dilution or alternative financing sources in the transcript increases concern about the company's ability to sustain operations through multiple binary events without resorting to dilutive financing, especially if avexitide faces regulatory or commercial setbacks.

Despite Amylyx's optimistic outlook, the company faces significant execution risk in the pivotal Phase III LUCIDITY trial for avexitide, as the trial's design relies heavily on historical data from five prior positive studies that may not be fully replicable in a larger, more diverse population. The management team acknowledged the conservative powering assumptions (35% effect size target despite prior 50-64% observed effects) and retained power for up to a 50% placebo effect, which they admitted they do not expect in PBH, suggesting awareness of potential variability in treatment response. Furthermore, the avoidance of commenting on baseline characteristics or placebo response during the Q&A, coupled with the reliance on blinded study data, raises questions about whether the enrolled population truly mirrors the prior successful trials, especially given the chronic and progressive nature of PBH where baseline hypoglycemia frequency and severity could significantly influence outcomes. Any failure to meet the primary endpoint or a result driven by high placebo response would severely undermine the investment thesis, particularly given the company's cash runway is explicitly tied to this milestone.
The commercial opportunity for avexitide in PBH, while touted as substantial at 160,000 patients in the U.S., remains highly uncertain and may be overestimated due to the nascent state of disease recognition and diagnostic practices. Management's claims analysis depends on identifying patients with bariatric surgery and documented nondiabetic hypoglycemia, then layering on symptoms like fatigue, dizziness, and seizures—criteria that may lack specificity and could inadvertently include patients with other causes of hypoglycemia or unrelated comorbidities. The dependence on centers of excellence for initial launch, with acknowledgment of only 50-60 patients per center, suggests a highly concentrated patient base that could limit early commercial scale and prolong the path to meaningful revenue. Moreover, the company's own admission that the ICD-10 code is not necessary for commercialization implies current diagnostic and coding practices are insufficient for reliable patient identification, posing a persistent barrier to market penetration that disease state education alone may not overcome quickly.
Amylyx's financial position, while currently supported by $279.8 million in cash and marketable securities as of Q1 2026, reflects a declining trend from $317 million at the end of the prior year, driven by increased operating expenses tied to the LUCIDITY trial and pre-launch activities. The $4 million milestone payment to Gubra for AMX0035 identification, coupled with rising R&D and SG&A expenditures, underscores the cash burn associated with advancing multiple pipeline programs concurrently. While management states this capital funds the runway into 2028, this projection is contingent on the successful and timely execution of the LUCIDITY trial, NDA submission, and potential approval—any delay in these milestones would rapidly erode the cash buffer. Additionally, the lack of discussion regarding potential dilution or alternative financing sources in the transcript increases concern about the company's ability to sustain operations through multiple binary events without resorting to dilutive financing, especially if avexitide faces regulatory or commercial setbacks.

Peer Comparison

Companies in the Drug Manufacturers - Specialty & Generic

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HLN	Haleon plc	88.07 Bn	103.29	6.00	11.45 Bn
2	TEVA	Teva Pharmaceutical Industries Ltd	35.75 Bn	23.02	2.06	16.63 Bn
3	ZTS	Zoetis Inc.	31.84 Bn	12.05	3.35	9.05 Bn
4	TAK	Takeda Pharmaceutical Co Ltd	27.18 Bn	-10.29	0.59	28.76 Bn
5	UTHR	UNITED THERAPEUTICS Corp	23.09 Bn	17.93	7.28	-
6	RDHL	RedHill Biopharma Ltd.	21.32 Bn	2,931.66	2.24	-
7	VTRS	Viatris Inc	19.96 Bn	-67.32	1.37	14.34 Bn
8	NBIX	Neurocrine Biosciences Inc	17.66 Bn	26.41	5.69	-

Research Tools

Developers

About

Investment Thesis

Consolidation Items Breakdown of Revenue (2023)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Consolidation Items Breakdown of Revenue (2023)

Peer Comparison

Create an account

Sign In

Reset Password